Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old
Sponsor: Boston Medical Center
Summary
This study is an open-label nonrandomized exploratory proof of concept and descriptive 4-year immunogenicity study to assess immunogenicity after administration of a 2-dose regimen of 9-valent human papillomavirus vaccine (9vHPV) vaccine separated by 12 months (months 0, 12).
Official title: An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Over a Four-year Follow up Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
Key Details
Gender
All
Age Range
4 Years - 8 Years
Study Type
INTERVENTIONAL
Enrollment
155
Start Date
2022-09-26
Completion Date
2028-12
Last Updated
2025-07-02
Healthy Volunteers
Yes
Conditions
Interventions
Gardasil9
The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
Locations (1)
Boston Medical Center
Boston, Massachusetts, United States